https://www.selleckchem.com/pr....oducts/3-3-cgamp.htm
Background With the increasing use of immune checkpoint inhibitors, tumor mutation burden (TM assessment is now routinely included in reports generated from targeted sequencing with large gene panels; however, not all patients require comprehensive profiling with large panels. Our study aims to explore the feasibility of using a small 56-gene panel as a screening method for TMB prediction. Methods TMB from 406 non-small cell lung cancer (NSCLC) patients was estimated using a large 520-gene panel simulated with the prospective TMB st
Like
Comment
Share
